Enamine and PAL Partner to Advance Fragment-Based Drug Discovery

Public-Private Collaboration Accelerates Early-Stage Therapeutic Research

Enamine has announced a strategic collaboration with the Pohang Accelerator Laboratory (PAL) to establish a framework for crystallographic fragment screening. The partnership combines PAL's publicly accessible research infrastructure with Enamine's expertise in compound libraries and medicinal chemistry, creating an integrated approach to accelerate fragment-based lead discovery (FBLD) for academic and industrial researchers.

Integrating Advanced Research Capabilities

The collaboration brings together PAL's state-of-the-art crystallography facilities and automated fragment screening workflows with Enamine's extensive fragment libraries and hit-to-lead optimization services. By linking structural biology with synthetic chemistry, the initiative aims to streamline the identification and progression of promising drug candidates.

Expanding Access to Drug Discovery Resources

The partnership introduces flexible collaboration models that make advanced fragment-based drug discovery resources more accessible. Researchers can leverage experimentally validated fragment libraries, structural analysis tools and rapid medicinal chemistry support, helping reduce barriers to early-stage pharmaceutical research and innovation.

Supporting Future Therapeutic Innovation

Fragment-based lead discovery has become an important strategy for identifying novel therapeutic compounds with improved precision and efficiency. By combining public research infrastructure with private-sector expertise, Enamine and PAL aim to accelerate the development of chemical probes and potential drug candidates for a broad range of biomedical applications.

Key Features

• Strategic collaboration between Enamine and Pohang Accelerator Laboratory (PAL)

• Crystallographic fragment screening platform

• Access to experimentally refined fragment libraries

• Automated screening workflows

• Hit-to-lead optimization support

• Flexible collaboration models for researchers

• Integration of structural biology and medicinal chemistry

• Supports fragment-based lead discovery (FBLD) research

Applications

• Fragment-based drug discovery

• Structure-guided drug design

• Medicinal chemistry research

• Lead identification and optimization

• Chemical probe development

• Academic biomedical research

• Pharmaceutical R&D

• Translational drug discovery programs

Accelerating Collaborative Drug Discovery

As pharmaceutical research increasingly relies on collaborative innovation, integrating advanced research infrastructure with specialized drug discovery expertise can significantly improve early-stage development. The partnership between Enamine and PAL provides researchers with an efficient framework for fragment screening and lead optimization, supporting faster progress toward the discovery of new therapeutic candidates.